Enginprime Medical
Enginprime Medical Raises $12M Series A for Percutaneous Heart Pump Devices
Enginprime Medical announced $12M in Series A financing on August 17, 2026. Enginprime Medical closed a $12M Series A led exclusively by Qiming Venture Partners to fund the China registration trial of its OpusOne percutaneous ventricular assist device.
Round details
The financing includes backing from Qiming Venture Partners. The company did not publish a valuation with the announcement.
- Round: Series A
- Capital announced: $12M
How the company plans to use the capital
Proceeds will fund the registration clinical trial of OpusOne in China. The company said the money will also support regulatory submissions and early-stage clinical development of the platform globally.
Why this matters for GTM teams
Enginprime Medical develops percutaneous ventricular assist device technology, and its lead product OpusOne is designed to deliver higher flow rates from a smaller catheter profile.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Enginprime Medical Series A announcement.
Company Info
Investors (1)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started